PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.
Yiting DongLele ZhaoJianchun DuanHua BaiDongsheng ChenSi LiYangyang YuMingzhe XiaoQin ZhangQianqian DuanTingting SunChuang QiJie WangZhijie WangPublished in: Cell proliferation (2022)
Our findings indicated that PAPPA2 mutation could serve as a novel indicator to stratify beneficiaries from ICIs therapy in NSCLC and SKCM, warranting further prospective studies.